Omnicell Inc (OMCL, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing. Omnicell Inc has a market cap of $3.33 billion; its shares were traded at around $83.99 with a P/E ratio of 91.28 and P/S ratio of 4.31. Omnicell Inc had annual average EBITDA growth of 16.50% over the past ten years. GuruFocus rated Omnicell Inc the business predictability rank of 3-star.
For the last quarter Omnicell Inc reported a revenue of $211.8 million, compared with the revenue of $197.9 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $787.3 million, an increase of 9.9% from last year. For the last five years Omnicell Inc had an average revenue growth rate of 16.8% a year.
The reported diluted earnings per share was 93 cents for the year, an increase of 75.5% from previous year. Over the last five years Omnicell Inc had an average EPS decline of 9.4% a year. The Omnicell Inc had an operating margin of 5.64%, compared with the operating margin of 0.8% a year before. The 10-year historical median operating margin of Omnicell Inc is 6.13%. The profitability rank of the company is 9 (out of 10).
At the end of the fiscal year, Omnicell Inc has the cash and cash equivalents of $67.2 million, compared with $32.4 million in the previous year. The long term debt was $135.4 million, compared with $194.9 million in the previous year. Omnicell Inc has a financial strength rank of 7 (out of 10).
At the current stock price of $83.99, Omnicell Inc is traded at 100.2% premium to its historical median P/S valuation band of $41.96. The P/S ratio of the stock is 4.31, while the historical median P/S ratio is 2.16. The intrinsic value of the stock is $21.06 a share, according to GuruFocus DCF Calculator. The stock gained 85.14% during the past 12 months.
CEO Recent Trades:
- Chairman, President and CEO Randall A Lipps sold 20,000 shares of OMCL stock on 02/22/2019 at the average price of $85.54. The price of the stock has decreased by 1.81% since.
Directors and Officers Recent Trades:
- Director Gary S Petersmeyer sold 1,000 shares of OMCL stock on 02/15/2019 at the average price of $82.26. The price of the stock has increased by 2.1% since.
- Director Gary S Petersmeyer sold 750 shares of OMCL stock on 02/12/2019 at the average price of $78.87. The price of the stock has increased by 6.49% since.
- EVP, Global R & D Jorge R. Taborga sold 2,509 shares of OMCL stock on 02/01/2019 at the average price of $64.26. The price of the stock has increased by 30.7% since.
For the complete 20-year historical financial data of OMCL, click here.
